NEWS: $375M Merger
CUBEBIO Announces Business Combination Agreement With Mountain Crest V to Become Publicly Listed
CUBEBIO, a Korean company with innovative early-stage cancer diagnosis technology using urine, has entered into a business combination agreement with Mountain Crest Acquisition Corp. V (MCAG). The deal aims to make CUBEBIO a publicly listed company on Nasdaq. Key details include:
1. Pre-transaction equity value for CUBEBIO: $375 million
2. Potential earn-out payment: $245 million if 2026 revenue reaches $42.7 million
3. Expected closing: First quarter of 2025
The transaction involves a merger and share swap, with CUBEBIO shareholders receiving PubCo Ordinary Shares. This marks Mountain Crest's fifth SPAC business combination, highlighting their experience in such deals.
1. Pre-transaction equity value for CUBEBIO: $375 million
2. Potential earn-out payment: $245 million if 2026 revenue reaches $42.7 million
3. Expected closing: First quarter of 2025
The transaction involves a merger and share swap, with CUBEBIO shareholders receiving PubCo Ordinary Shares. This marks Mountain Crest's fifth SPAC business combination, highlighting their experience in such deals.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1692Followers
93Following
13KVisitors
Follow
73296040 : sounds bullish no?
Jaguar8 OP 73296040 : Yes